• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Enter Romania And Bulgaria

Enter Romania And Bulgaria

January 4, 2007
CenterWatch Staff

The European Union (EU) will have two new member states next month: Romania and Bulgaria. Both countries are ready to implement the EU Clinical Trials Directive, but their membership may have broader implications for clinical research than just harmonized regulations.

Fast patient recruitment - one of the biggest drug development bottlenecks in the West - has been Eastern Europe’s trump card. Clinical trials that take only weeks to recruit patients for in Eastern Europe can take months or even a year in Western Europe.

The major difference between Western and Eastern Europe is the structure of their respective healthcare systems. Eastern European countries have very large hospitals, each dedicated to one therapeutic area where all patients with that disease go to seek treatment. These countries also only have one national healthcare system in which all patients are identified...

It’s not unusual for patient visits for a clinical trial conducted in Eastern Europe to begin within a week of site initiation. But, if Poland’s accession to the EU is any guide, Romania and Bulgaria will need to be careful if they want to avoid some of the pitfalls associated with EU membership.

Poland has suffered a bit of “brain drain,” leaving some medical departments almost deserted by doctors who have emigrated to the UK or some of the Nordic countries. Doctors make very poor salaries in Poland and those who have English fluency and can find employment in the West leave to improve their lot. This means the doctors who are left behind are busier and have less time to conduct clinical trials.

The governments of Romania and Bulgaria will need to consider raising physician salaries to keep them in the country and to continue attracting clinical research funds. These funds are an important contribution to their hospitals’ budgets. Competition for physicians to conduct clinical trials could increase.

Competition for patients for clinical trials could also increase. Countries that accede to the EU must provide a private healthcare system, which could siphon off many of the patients normally funneled in the government-funded centralized healthcare system. With top doctors leaving Romania and Bulgaria for the West and patients opting for private healthcare, enrollment timelines could begin to resemble the West’s. But most feel that in the short term, this scenario is unlikely. Ten or so years down the road, it may be another story.

Aside from fast patient recruitment, Romania and Bulgaria also offer an excellent technology infrastructure. Investment in technology in both countries has been a priority in recent years, and both physician investigators and other clinical research personnel there are adept at using electronic data capture (EDC) and are willing to embrace new technolog. This is an important advantage for countries that want to participate in global clinical trial programs.

How each country handles EU membership will be watched closely by other Eastern European countries that have applied—Croatia, Serbia and Montenegro, which became officially independent from Serbia in June.

In the short term, there should be very few differences, outside procedural ones, in conducting clinical research in Romania and Bulgaria after accession to the EU. But their respective governments would be wise to invest in their physicians for the long term so that they preserve the advantages they offer for conducting clinical research.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing